According to GlobalData’s medical device pipeline database, six White Blood Count Point of Care (POC) Tests devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, five are in active development, while the remaining one is in an inactive stage of development. All devices are in the early stages of development.
A WBC count is a blood test to measure the number of white blood cells (WBCs) in the blood. There are five major types of white blood cells are Basophils, Eosinophils, Lymphocytes (T cells, B cells, and Natural Killer cells), Monocytes, and Neutrophils. A WBC POC is performed to screen for or diagnose a variety of conditions that can affect white blood cells (WBC) such as an infection, inflammation, or a disease that affects the production or survival of WBCs; to monitor treatment of a blood disorder or to monitor therapy that is known to affect WBCs. One WBC cartridge/microcuvette refers to one test.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
See Also:
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed White Blood Count Point of Care (POC) Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of White Blood Count Point of Care (POC) Tests devices. Overall, most of these White Blood Count Point of Care (POC) Tests pipeline devices are being developed by private entities.
Key players involved in the active development of White Blood Count Point of Care (POC) Tests include Abionic and PortaScience.
For a complete picture of the developmental pipeline for White Blood Count Point of Care (POC) Tests devices, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
